Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients

Journal of Pharmacological Sciences

Volumn 96, Issue 4, 2004, Pages 465-473

  Hamed, Sherifa A ^a   Abdellah, Moustafa M ^a   El Melegy, Nagla ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Antiepileptic drug; Antioxidant; Electrolyte; Oxidative stress; Trace element

Indexed keywords

ANTICONVULSIVE AGENT; ANTIOXIDANT; CALCIUM; CARBAMAZEPINE; CERULOPLASMIN; COPPER; ELECTROLYTE; FREE RADICAL; GLUTATHIONE PEROXIDASE; MAGNESIUM; MALONALDEHYDE; PHENYTOIN; POTASSIUM; SELENIUM; SODIUM; TRACE ELEMENT; URIC ACID; VALPROIC ACID; ZINC;

ADOLESCENT; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; COPPER BLOOD LEVEL; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; EPILEPSY; FEMALE; HUMAN; LIPID PEROXIDATION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MONOTHERAPY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; SODIUM BLOOD LEVEL; ZINC BLOOD LEVEL;

EID: 12444315074     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FPJ04032X     Document Type: Article

References (75)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34:453-468.
2. Sheth DP. Hypocalcemic seizures in neonates. Am J Emerg Med. 1997;15:141-143.
3. Iihan A, Uz E, Kali S, Var A, Akyol O. Serum and hair trace elements levels in patients with epilepsy and healthy subjects: Does the antiepileptic therapy affect the element concentrations of hair. Eur J Neurol. 1999;6:705-709.
4. Maertens P, Dyken P, Graf W, Pippenger C, Chronister R, Shah A. Free radicals, anticonvulsants and the neuronal ceroid lipofuscinosis. Am J Med Genet. 1995;57:225-228.
5. Yüksel A, Cengiz M, Seven M, Ulutin T. Erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children with valproate and carbamzepine monotherapy. J Basic Clin Pharmacol. 2000;11:73-81.
6. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant activities in children with, a serious side adverse experience related to valproic acid therapy. Neuropediatrics. 1998;29:195-201.
7. Niketic V, Ristic S, Saicic ZS, Spasic M, Buzadzic B, Stojkovic M. Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Farmaco. 1995;50:811-813.
8. Verrotti A, Basciani F, Trotta D, Pomilio MP, Morgese G, Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002;48:71-75.
9. Abdulla A, Ibse I. Utesluter normalt zinc serum zinkbrist? Lakartidningen. 1976;73:2104-2105. (text in Swedish with English abstract)
10. Pippenger CE, Meng X, Von Lente F, Rothner AD. Valproate therapy suppresses GSH.PX and SOD enzyme activity. A possible mechanism for VPA induced idiosyncratic drug toxicity. Clin Chem. 1989;35:1173.
11. Ebadi M, Wilt S, Ramaley R, Swanson S, Mebus C. The role of zinc and zinc-binding proteins in regulation of glutamic acid decarboxylase in brain. In: Evangenopoulas AD, editor. Progress in clinical and biological research. Vol. 144 Part A. Chemical and biological aspects of vitamin B6 catalysis. New York: Alan R. Liss; 1984. p. 255-275.
12. Kürekçi AE, Alpay F, Tanindi S, Gokcay E, Ozcan O, Akin R, et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving AEDs therapy. Epilepsia. 1995;36:600-604.
13. Burk RF, Lawrence PH, Lane JM. Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diguat administration: effect of selenium deficiency. J Clin Invest. 1980;65:1024-1031.
14. Ames BN, Catheart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858-6862.
15. Halliwell B, Gulteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophysics. 1990;250:1-8.
16. Miller N, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. Replacement of metmyoglobin as a peroxidase sources by horseradish peroxidase. Clin Sci. 1993;84:407-412.
17. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods by adding the BHT solution to prevent further lipid peroxidation during boiling. Methods Enzymol. 1978;52:302-310.
18. Houchin J. Methods of determination of serum ceruloplasmin level. Am J Biochem. 1958;13:41.
19. Mills GC. The purification and properties of glutathione peroxidase of erythrocyte. J Biol Chem. 1959;234:502-506.
20. Hafeman DG, Sunde RA, Hockstka W. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J Nutr. 1974;104:580-587.
21. Hurd RW, Wilder BJ, Street JJ, Sciscent BL. Zinc binding by valproic acid. Neuroscience. Abstr. 1981;7:813.
22. Palm R, Hallmans G. Zinc and copper metabolism in phenytoin therapy. Epilepsia. 1982;23:453-461.
23. Abbott LC, Nejad HH, Bottje WG, Hassan AS. Glutathione levels in specific brain regions of genetically epileptic (tg/tg) mice. Brain Res Bull. 1990;52:629-631.
24. Smith WG, Bone I. Copper, zinc and magnesium plasma levels in epilepsy. J Neurol Neurosurg Psychiatry. 1982;45:1072.
25. Barbeau A, Donaldson J. Zinc, taurine and epilepsy. Arch Neurol. 1974;30:52-58.
26. Ghose K, Taylor A. Hypercupraemia induced by antiepileptic drugs. Hum Toxicol. 1983;3:519-529.
27. Werther CA, Clud H, Ohtake M, Tamura T. Effects of long-term administration of anticonvulsants on copper, zinc and ceruloplasmin levels. Drug Nutr Interact. 1986;4:269-274.
28. Davidson SLW, Ward NI. Abnormal aluminum, cobalt, manganese, strontium and zinc concentrations in untreated epilepsy. Epilepsy Res. 1988;1:3-13.
29. Schott GD, Delves HT. Plasma zinc levels with anticonvulsant therapy. Br J Clin Pharmacol. 1978;5:279-280.
30. Shaw JCL. Trace elements in the fetus and young infant. Am J Dis Child. 1979;133:1260-1264.
31. Kuzuya T, Hasegawa T, shimizu K, Nebeshima T. Effect of antiepileptic drugs on serum zinc, copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol. 1993;31:61-65.
32. Yuen WC, Whiteoak R, Thompson RP. Zinc concentrations in leukocytes of patients receiving antiepileptic drugs. J Clin Pathol. 1988;41:553-555.
33. Steidl L, Tolde I, Svomova V. Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate. Magnesium. 1987;6:284-295.
34. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol. 1987;10:80-86.
35. Altunbasak S, Biatmakoui F, Baytok V, Herguner O, Burgut HR, Kayrin L. Serum and hair zinc levels in epileptic children taking valproic acid. Biol Trace Elem Res. 1997;58:117-125.
36. Taylor A, Ghose K. Diurnal variation of serum copper and zinc in epileptics receiving anticonvulsants. Hum Toxicol. 1986;5:195-200.
37. Lifschitz MD, Henkin RI. Circadian variation in copper and zinc in man. J App Physiol. 1971;31:88-92.
38. Rail TW, Schleifer LS. Drugs effective in the therapy of epilepsies. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Singapore: Pergamon Press; 1991. p. 436-462.
39. Pippenger CE, Meng X, van Lente F. Alternative approaches to the prediction of antiepileptic idiosyncratic or drug-drug interactions. New York: Demos; 1989. p. 293-307.
40. Liu CS, Wu HM, Kao SH, Wei YH. Phenytoin-mediated oxidative stress in seum of female epileptics: a possible pathogenesis in fetal hydantoin syndrome. Hum Exp Toxicol. 1997;31:61-65.
41. Liu C, Wu H, Kao S, Wei Y. Serum trace elements, glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine monotherapy. Clin Neuropharmacol. 1998;21:62-64.
42. Shah QA, Jamil AA, Gupta VP, Kabiraj MM, Shah AH. Changes in serum electrolytes in childhood epilepsy: A hospital-based prospective. Greenwich J Sci Technol. 2001;2:18-27.
43. Fichsel H, Niewerth B, Schlehbusch H. Influence of antiepileptic drugs on copper and ceruloplasmin concentrations in epileptic children and juvenile in antiepileptic therapy. In: Oxley J, Janz D, Meinardi H, editors. Chronic toxicity of antiepileptic drugs. New York: Raven Press; 1983. p. 85-90.
44. Tange SM. Hair zinc and copper concentrations in patients with epilepsy. Zhonghua Shen Jing Shen Ke Za Zhi. 1991;24:94-97, 124-125. (abstract in Chinese)
45. Kaji M, Ito M, Okuno T, Momoi T, Sasaki H, Yamanaka C, et al. Serum copper and zinc levels in epileptic children with valproate. Epilepsia. 1992;33:555-557.
46. Hurd RW, Van Rinsvelt HA, Wilder BJ, Karas B, Maenhaut W, De Reu L. Selenium, zinc and copper changes in valproic acid: possible correlation to drug side effects. Neurology. 1984;34:1393-1395.
47. Sozuer DT, Baruteu UB, Karakoc Y, Yalcin E, Onen S. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol. 1995;6:265-269.
48. Motta E, Miller K, Ostrowska Z. Concentration of copper and ceruloplasmin in serum of patients treated for epilepsy. Wiad Lek. 1998;51:156-161. (text in Polish with English abstract)
49. Rotruck JT, Pope AI, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588-590.
50. Hurd RW, Wilder BJ, Van Rinsvelt HA. Valproate, birth defects and zinc. Lancet. 1983;22:181.
51. Rude RK. Magnesium metabolism and deficiency. Endocrinol Metab Clin N Am. 1993;22:377-395.
52. Nzeh DA, Erasmus RT, Aiyedun BA. Serum electrolytes and protein changes after intravenous injection of sodium and meglumine diatrizoate (Urograffin-370). Aft J Med Sci. 1994;23:35-37.
53. Kiviranta T, Tuomisto L, Airaksine EM. Osmolarity and electrolytes in cerebrospinal fluid and serum of febrile children with and without seizures. Eur J Pediatr. 1996;155:120-125.
54. Kandel ER. Transmitter release. In: Principles of neuronal science. Kandel ER, Schwartz JH, Vessel TM, editors. New York: Elsevier; 1991. p. 194-212.
55. Roitg I, Jamard B, Constantin A, Cantagrel A, Mazieres B, Laroche M. Severe refractory hypocalcemia in patients with enteropathy: consider hypomagnesemia. Joint Bone Spine. 2004;71:252-253.
56. Leaver DD, Parkinson GB, Schneider KM. Neurological consequences of magnesium deficiency: correlations with epilepsy. Clin Exp Pharmacol Physiol. 1987;14:361-370.
57. Biochonski R. Electrochemical blood properties in epileptic children. Neurol Neurochir Pol. 1976;10:249-254.
58. White HS, Chow SY, Yen-Chow YC, Woodbury DM. Effect of elevated potassium on the ion content of mouse astrocytes and neurons. Can J Physiol Pharmacol. 1992;70 suppl:S263-S268.
59. Natelson S, Miletich DJ, Seals CF, Visintine DJ, Albrecht RF. Clinical biochemistry of epilepsy-1-nature of the disease and a review of chemical findings in epilepsy. Clin Chem. 1979;25:889-897.
60. Koivikko MJ, Valikangas SL. Hyponatraemia during carbamazepine therapy in children. Neuropediatrics. 1983;14:93-96.
61. Rude RK. Physiology of magnesium metabolism and the important role of magnesium in potassium deficiency. Am J Cardiol. 1989;63:31G-34G.
62. Huang EP. Metal ions and synaptic transmission: think zinc. Proc Natl Acad Sci USA. 1997;94:13386-13387.
63. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JI, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr. 1979;95:142-144.
64. Young RSK, Bergman I, Gang DL, Richardson EP. Fatal Reye-like syndrome associated with valproic acid. Ann Neurol. 1980;7:389.
65. Lindhout DH, Oppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia. 1984;25:77-83.
66. Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chem Acta. 2001;303:19-24.
67. Martinez-Ballesteros C, Pita-Calandre E, Sanch-Gonzalez Y, Rodriguez-Lopez CM, Agil A. Lipid peroxidation in adult patients treated with valproic acid. Rev Neurol. 2004;38:101-106. (text in Spanish with English abstract)
68. Tutor JC, Fernandez MP, Paz JM. Serum copper concentration and hepatic enzyme induction during long therapy with anticonvulsants. Clin Chem. 1982;28:1367-1370.
69. Mahle C, Dasgupta A. Decreased total antioxidant capacity and elevated lipid hydroperoxide concentrations in sera of epileptic patients receiving phenytoin. Life Sci. 1997;61:437-443.
70. Tutor-Crespo MJ, Hermida J, Tutor JC. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring specific oxidase activity of ceruloplasmin. Epilepsy Res. 2003;56:147-153.
71. Cotario D, Evans S, Zaidman JL, Marcus O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem Pharmacol. 1990;40:589-593.
72. Weber GF, Maertens P, Meng X, Pippenger CE. Glutathione peroxidase deficiency and childhood seizures. Lancet. 1991;337:1443-1444.
73. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet. 1985;10:80-90.
74. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against exctiotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53:613-625.
75. Maesaka JK, Fishban S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis. 1998;32:917-933.